Agilent Raman Solutions for Pharmaceutical QC

Significance of the Topic

Raman spectroscopy plays a critical role in pharmaceutical quality control by enabling rapid, non-destructive identification and quantitative analysis of raw materials and finished dosage forms. Technologies that streamline workflows, reduce reliance on wet chemistry, and support regulatory compliance help manufacturers accelerate release timelines, lower operational costs, and maintain consistent product quality.

Objectives and Overview

This application note introduces Agilent’s portfolio of Raman solutions designed for pharmaceutical QC. The key aims are to:

• Demonstrate raw material identification through transparent and opaque containers without sampling.
• Present a handheld SORS-based system for on-the-spot verification.
• Describe a portable solution for challenging container types.
• Showcase a transmission Raman instrument for rapid content uniformity, assay, and polymorph analysis in solid dosage forms.

Methodology and Used Instrumentation

Agilent employs two complementary Raman approaches:

• Spatially Offset Raman Spectroscopy (SORS) for container-agnostic material identification.
• Transmission Raman Spectroscopy (TRS) for bulk analysis of tablets and capsules with minimal sample preparation.

Used Instrumentation:

• Agilent Vaya: Handheld SORS system for fast ID through clear vials, colored liners, plastic tubs, paper sacks, and amber glass bottles.
• Agilent RapID: Portable, wheeled SORS system for opaque containers including common excipient and API packages (excludes metal and fiber drums).
• Agilent TRS100: Bench-top TRS system for quantitative analysis (content uniformity, assay, polymorph discrimination) of intact tablets, capsules, and powders in under 10 seconds per sample.

Main Results and Discussion

Agilent’s SORS systems enable 100% ID testing directly in quarantine areas, eliminating sample transfer and booth requirements. Vaya achieves material verification in seconds through a wide range of container types, while RapID extends capability to the most challenging opaque packages. The TRS100 dramatically reduces QC cycle times: a full eight-batch content uniformity and assay campaign requires roughly 120 minutes, compared to over 1,700 minutes for traditional HPLC workflows. The transmission Raman approach also offers high sensitivity to low-level APIs (0.1–1% w/w) and can distinguish solid-state forms alongside standard assay measurements.

Benefits and Practical Applications

• Non-destructive, minimal or no sample preparation.
• Fast screening and quantitative testing (seconds per sample).
• Direct warehouse or production-line deployment.
• Reduced consumables and solvent usage compared to wet chemistry.
• Support for 21 CFR Part 11 compliance in GMP environments.
• Scalable from low-volume R&D screening to 100% incoming goods ID.

Future Trends and Potential

Advancements in Raman QC are expected to focus on deeper integration with automated material handling and AI-driven spectral interpretation. Expanded spectral libraries, real-time inline monitoring, and miniaturized, networked devices will further enhance throughput and data connectivity. Emerging use cases include continuous manufacturing QC, end-to-end digital batch records, and broader adoption of non-invasive analytical methods across pharmaceutical operations.

Conclusion

Agilent’s Raman solutions offer a comprehensive toolkit for pharmaceutical QC, combining container-agnostic raw material ID with high-speed quantitative transmission Raman analysis. These technologies deliver significant time and cost savings, support regulatory compliance, and future-proof QC workflows against evolving industry requirements.

References

Agilent Technologies Application Note 5994-1805EN, February 2020